Health authorities have no intention to re-evaluate efficacy of Ursa

Published: 2013-09-12 07:00:00

Updated: 2013-09-12 07:00:00

The Ministry of Food and Drug Safety (MFDS) said it has not any plan to re-evaluate the efficacy of Ursa produced by Daewoong Pharm amid escalating dispute over the therapeutic effect of the liver function enhancer.

In a phone-call with Yakup Shinmoon, a local trade paper, the MFDS official Le...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK